News & Events about Jazz Pharmaceuticals Plc.
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating...
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN, Jan. 3, 2023 DUBLIN, Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2022 Earnings Call Transcript November 9, 2022 Jazz Pharmaceuticals plc beats earnings expectations. Reported EPS is $5.17, expectations were $4.66. Operator: Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call...
Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks lead drug candidate, zanidatamab, in the U.S., Europe and Japan. The new cash builds on a $50 million payment earlier this year and comes after Tuesdays release of positive ...
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab PR Newswire DUBLIN and VANCOUVER, BC, Dec. 21, 2022 Follows positive top-line...